The nation's second trial over health effects of the drug Vioxx got swamped in New Jersey last month, as a jury categorically rejected claims that failure to warn about the painkiller's risks caused a user's heart attack.
Merck Wins Big in Jersey Vioxx Trial
The nation's second trial over health effects of the drug Vioxx got swamped in New Jersey last month, as a jury categorically rejected claims that failure to warn about the painkiller's risks caused a user's heart attack. The jury found, 8-1, that Merck & Co. properly alerted prescribing physicians to a link between Vioxx and an increased risk of cardiovascular events, and found unanimously that there were no consumer-fraud violations in the way Merck marketed Vioxx to physicians. As a result, the jury never reached the question of proximate causation of postal worker Frederick "Mike" Humeston's heart attack.
This premium content is locked for LawJournalNewsletters subscribers only
ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN LawJournalNewsletters
- Stay current on the latest information, rulings, regulations, and trends
- Includes practical, must-have information on copyrights, royalties, AI, and more
- Tap into expert guidance from top entertainment lawyers and experts
Already have an account? Sign In Now
For enterprise-wide or corporate access, please contact Customer Service at [email protected] or call 1-877-256-2473.






